As already mentioned above, co-administration of selective BRAF and MEK inhibitors (dabrafenib and trametinib, respectively) has received FDA approval for treatment of locally advanced and metastatic BRAF V600E-positive ATCs [103]. Here, BRAF is linked to Ehlers-Danlos syndrome, musculocontractural type.